CPHI
China Pharma Holdings, Inc.
Drug Manufacturers - Specialty & Generic
Market Cap$9M
5Y Perf.-99.8%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
CPHI vs SGBX
Revenue, margins, valuation, and 5-year total return — side by side.
SGBX
Safe & Green Holdings Corp.
Manufacturing - Metal Fabrication
Market Cap$33K
5Y Perf.-99.9%
CPHI vs SGBX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | CPHI | SGBX |
|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Manufacturing - Metal Fabrication |
| Market Cap | $9M | $33K |
| Revenue (TTM) | $4M | $3M |
| Net Income (TTM) | $-3M | $-19M |
| Gross Margin | -8.4% | -87.3% |
| Operating Margin | -79.8% | -375.8% |
| Total Debt | $4M | $7M |
| Cash & Equiv. | $627K | $376K |
CPHI vs SGBX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
CPHI
SGBX
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| China Pharma Holdin… (CPHI) | 100 | 0.2 | -99.8% |
| Safe & Green Holdin… (SGBX) | 100 | 0.1 | -99.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CPHI vs SGBX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: CPHI leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Safe & Green Holdings Corp. is the stronger pick specifically for capital preservation and lower volatility and dividend income and shareholder returns. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
CPHI
China Pharma Holdings, Inc.
The Income Pick
CPHI carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 1 yrs, beta 1.18
- Rev growth -35.4%, EPS growth 6.9%, 3Y rev CAGR -22.3%
- -99.5% 10Y total return vs SGBX's -100.0%
Best for: income & stability and growth exposure
SGBX
Safe & Green Holdings Corp.
The Defensive Pick
SGBX is the clearest fit if your priority is sleep-well-at-night and defensive.
- Lower volatility, beta 0.45, current ratio 0.08x
- Beta 0.45, yield 100.0%, current ratio 0.08x
- Beta 0.45 vs CPHI's 1.18
Best for: sleep-well-at-night and defensive
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | CPHI | -35.4% revenue growth vs SGBX's -69.9% |
| Quality / Margins | CPHI | -78.7% margin vs SGBX's -5.7% |
| Stability / Safety | SGBX | Beta 0.45 vs CPHI's 1.18 |
| Dividends | SGBX | 100.0% yield; 1-year raise streak; the other pay no meaningful dividend |
| Momentum (1Y) | CPHI | -71.9% vs SGBX's -96.3% |
| Efficiency (ROA) | CPHI | -20.0% ROA vs SGBX's -35.6%, ROIC -32.2% vs -625.7% |
CPHI vs SGBX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2021
FY 2024
CPHI vs SGBX — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLCPHILAGGINGSGBX
SGBXSafe & Green Holdings…
0leads
CPHIChina Pharma Holdings…
3leads
6 Total Categories
CATEGORYLEADERvs SGBXMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
CPHI5/6
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
CPHI5/6
Total Returns1Y, 3Y, 5Y total returns with dividends
CPHI5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
CPHI leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
CPHI and SGBX operate at a comparable scale, with $4M and $3M in trailing revenue. Profitability is closely matched — net margins range from -78.7% (CPHI) to -5.7% (SGBX). On growth, CPHI holds the edge at -31.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | CPHIChina Pharma Hold… | SGBXSafe & Green Hold… |
|---|---|---|
| RevenueTrailing 12 months | $4M | $3M |
| EBITDAEarnings before interest/tax | -$2M | -$12M |
| Net IncomeAfter-tax profit | -$3M | -$19M |
| Free Cash FlowCash after capex | -$129,606 | -$5M |
| Gross MarginGross profit ÷ Revenue | -8.4% | -87.3% |
| Operating MarginEBIT ÷ Revenue | -79.8% | -3.8% |
| Net MarginNet income ÷ Revenue | -78.7% | -5.7% |
| FCF MarginFCF ÷ Revenue | -3.2% | -155.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | -31.3% | -40.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +26.1% | +88.9% |
CPHI leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
Evenly matched — CPHI and SGBX each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | CPHIChina Pharma Hold… | SGBXSafe & Green Hold… |
|---|---|---|
| Market CapShares × price | $9M | $32,963 |
| Enterprise ValueMkt cap + debt − cash | $12M | $7M |
| Trailing P/EPrice ÷ TTM EPS | -1.95x | -0.00x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 2.03x | 0.01x |
| Price / BookPrice ÷ Book value/share | 1.19x | — |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — CPHI and SGBX each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
CPHI leads this category, winning 5 of 6 comparable metrics.
Profitability & Efficiency
CPHI delivers a -37.6% return on equity — every $100 of shareholder capital generates $-38 in annual profit, vs $-77 for SGBX.
| Metric | CPHIChina Pharma Hold… | SGBXSafe & Green Hold… |
|---|---|---|
| ROE (TTM)Return on equity | -37.6% | -77.2% |
| ROA (TTM)Return on assets | -20.0% | -35.6% |
| ROICReturn on invested capital | -32.2% | -625.7% |
| ROCEReturn on capital employed | -47.0% | — |
| Piotroski ScoreFundamental quality 0–9 | 2 | 2 |
| Debt / EquityFinancial leverage | 0.46x | — |
| Net DebtTotal debt minus cash | $3M | $7M |
| Cash & Equiv.Liquid assets | $626,879 | $375,873 |
| Total DebtShort + long-term debt | $4M | $7M |
| Interest CoverageEBIT ÷ Interest expense | -28.22x | -13.81x |
CPHI leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
CPHI leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CPHI five years ago would be worth $16 today (with dividends reinvested), compared to $5 for SGBX. Over the past 12 months, CPHI leads with a -71.9% total return vs SGBX's -96.3%. The 3-year compound annual growth rate (CAGR) favors CPHI at -69.5% vs SGBX's -87.5% — a key indicator of consistent wealth creation.
| Metric | CPHIChina Pharma Hold… | SGBXSafe & Green Hold… |
|---|---|---|
| YTD ReturnYear-to-date | -56.5% | -52.9% |
| 1-Year ReturnPast 12 months | -71.9% | -96.3% |
| 3-Year ReturnCumulative with dividends | -97.2% | -99.8% |
| 5-Year ReturnCumulative with dividends | -99.8% | -100.0% |
| 10-Year ReturnCumulative with dividends | -99.5% | -100.0% |
| CAGR (3Y)Annualised 3-year return | -69.5% | -87.5% |
CPHI leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — CPHI and SGBX each lead in 1 of 2 comparable metrics.
Risk & Volatility
SGBX is the less volatile stock with a 0.45 beta — it tends to amplify market swings less than CPHI's 1.18 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CPHI currently trades 20.2% from its 52-week high vs SGBX's 1.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | CPHIChina Pharma Hold… | SGBXSafe & Green Hold… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.18x | 0.45x |
| 52-Week HighHighest price in past year | $2.60 | $96.00 |
| 52-Week LowLowest price in past year | $0.50 | $0.79 |
| % of 52W HighCurrent price vs 52-week peak | +20.2% | +1.0% |
| RSI (14)Momentum oscillator 0–100 | 35.1 | 35.2 |
| Avg Volume (50D)Average daily shares traded | 26K | 503K |
Evenly matched — CPHI and SGBX each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
SGBX is the only dividend payer here at 100.00% yield — a key consideration for income-focused portfolios.
| Metric | CPHIChina Pharma Hold… | SGBXSafe & Green Hold… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | +100.0% |
| Dividend StreakConsecutive years of raises | 1 | 1 |
| Dividend / ShareAnnual DPS | — | $13.85 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
CPHI leads in 3 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 2 categories are tied.
Best OverallChina Pharma Holdings, Inc. (CPHI)Leads 3 of 6 categories
Loading custom metrics...
CPHI vs SGBX: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is CPHI or SGBX a better buy right now?
For growth investors, China Pharma Holdings, Inc.
(CPHI) is the stronger pick with -35. 4% revenue growth year-over-year, versus -69. 9% for Safe & Green Holdings Corp. (SGBX). The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — CPHI or SGBX?
Over the past 5 years, China Pharma Holdings, Inc.
(CPHI) delivered a total return of -99. 8%, compared to -100. 0% for Safe & Green Holdings Corp. (SGBX). Over 10 years, the gap is even starker: CPHI returned -99. 5% versus SGBX's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — CPHI or SGBX?
By beta (market sensitivity over 5 years), Safe & Green Holdings Corp.
(SGBX) is the lower-risk stock at 0. 45β versus China Pharma Holdings, Inc. 's 1. 18β — meaning CPHI is approximately 164% more volatile than SGBX relative to the S&P 500.
04Which is growing faster — CPHI or SGBX?
By revenue growth (latest reported year), China Pharma Holdings, Inc.
(CPHI) is pulling ahead at -35. 4% versus -69. 9% for Safe & Green Holdings Corp. (SGBX). On earnings-per-share growth, the picture is similar: Safe & Green Holdings Corp. grew EPS 69. 1% year-over-year, compared to 6. 9% for China Pharma Holdings, Inc.. Over a 3-year CAGR, CPHI leads at -22. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — CPHI or SGBX?
China Pharma Holdings, Inc.
(CPHI) is the more profitable company, earning -104. 6% net margin versus -341. 2% for Safe & Green Holdings Corp. — meaning it keeps -104. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CPHI leads at -101. 3% versus -195. 0% for SGBX. At the gross margin level — before operating expenses — SGBX leads at -4. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — CPHI or SGBX?
In this comparison, SGBX (100.
0% yield) pays a dividend. CPHI does not pay a meaningful dividend and should not be held primarily for income.
07Is CPHI or SGBX better for a retirement portfolio?
For long-horizon retirement investors, Safe & Green Holdings Corp.
(SGBX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 45), 100. 0% yield). Both have compounded well over 10 years (SGBX: -100. 0%, CPHI: -99. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between CPHI and SGBX?
These companies operate in different sectors (CPHI (Healthcare) and SGBX (Industrials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: CPHI is a small-cap quality compounder stock; SGBX is a small-cap income-oriented stock. SGBX pays a dividend while CPHI does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(CPHI: -31.3% · SGBX: -40.0%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.